Galderma achieved a major financial milestone in the first half of 2026, reporting net sales of $3.134 billion. This represents a 24.6% increase at constant currency, prompting the company to raise its full-year net sales guidance.
The $3.134 billion H1 milestone
Galderma has surpassed the 3 billion USD mark in net sales for the first six months of a calendar year for the first time in its history. According to the company's financial results, this growth was not limited to a single region but was broad-based, with double-digit increases recorded in both the United States and international markets.
This performance suggests that Galderma's strategy of diversifying across all product categories is yielding results.. By maintaining growth across the board, Galderma has reduced its reliance on any single market or product line, creating a more resilient revenue stream as it enters the second half of 2026.
A 67.9% surge in Therapeutic Dermatology
While all sectors grew, the Therapeutic Dermatology category saw an explosive year-on-year increase of 67.9% at constant currency. A primary driver of this success was Nemolizumab, which generated 433 million USD in net sales during the first half of the year, as reported in the company's filing.
In comparison, other categories saw more modest, though still strong, growth. Injectable Aesthetics grew by 12.1%, while Dermatological Skincare increased by 16.4%. The disparity between the therapeutic surge and the aesthetic growth indicates a significant shift in where Galderma is finding its most aggressive expansion opportunities.
Relfydess and the 33-market expansion
Galderma is aggressively scaling its presence in the aesthetics market through Relfydess (RelabotulinumtoxinA). The company noted that Relfydess continues to ramp up its global footprint, having already secured approvals in 33 international markets.
This expansion is part of a larger investment in medical education and science-based innovation that Galderma has accelerated beyond its initial expectations. by securing approvals in dozens of markets, Galderma is positioning Relfydess to compete directly with established toxin brands on a global scale.
The 42.8% jump in Core EBITDA
Profitability has scaled faster than revenue, with Galderma's Core EBITDA reaching 802 million USD. This represents a 42.8% increase year-on-year at constant currency, resulting in a Core EBITDA margin of 25.6%.
This margin expansion suggests that Galderma is achieving significant operational efficiencies as it scales. The ability to grow the bottom line at nearly double the rate of net sales indicates that the company's current growth phase is highly accretive.
The missing details on revised 2026 guidance
Despite the announcement that Galderma has raised its net sales guidance for the full year, the report does not provide the specific new dollar target or the exact percentage increase expected by year-end. Furthermore, while the report mentions "International markets," it does not break down which specific countries or regions contributed most to the double-digit growth.
It also remains unclear how much of the 16.4% growth in Dermatological Skincare was driven by new product launches versus the organic growth of existing leacy brands. Without these specifics, investors are left to infer the sustainability of the current trajectory based on the H1 snapshot alone.
Comments 0